{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T05:17:11Z","timestamp":1783487831642,"version":"3.55.0"},"reference-count":35,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,11]]},"DOI":"10.1097\/wnf.0b013e318166da60","type":"journal-article","created":{"date-parts":[[2008,11,24]],"date-time":"2008-11-24T08:11:17Z","timestamp":1227514277000},"page":"313-318","source":"Crossref","is-referenced-by-count":47,"title":["The Long-term Effect of Tetrabenazine in the Management of Huntington Disease"],"prefix":"10.1097","volume":"31","author":[{"given":"Alfonso","family":"Fasano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Cadeddu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arianna","family":"Guidubaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Piano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Soleti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Zinzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Rita","family":"Bentivoglio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-1-20210203","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1136\/jnnp.47.8.848","article-title":"Effect of neuroleptic treatment on involuntary movements and motor performances in Huntington's disease.","volume":"47","author":"Girotti","year":"1984","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R2-1-20210203","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1046\/j.1468-1331.2002.0354e.x","article-title":"Risperidone in chorea and psychosis of Huntington's disease.","volume":"9","author":"Erdemoglua","year":"2002","journal-title":"Eur J Neurol"},{"key":"R3-1-20210203","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1046\/j.1468-1331.2002.0354f.x","article-title":"Riluzole and olanzapine in Huntington's disease.","volume":"9","author":"Bonelli","year":"2002","journal-title":"Eur J Neurol"},{"key":"R4-1-20210203","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1002\/1531-8257(199905)14:3<398::AID-MDS1003>3.0.CO;2-F","article-title":"Pathophysiology of chorea and bradykinesia in Huntington's disease.","volume":"14","author":"Berardelli","year":"1999","journal-title":"Mov Disord"},{"key":"R5-1-20210203","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/ana.410120308","article-title":"Tetrabenazine has properties of a dopamine receptor antagonist.","volume":"12","author":"Login","year":"1982","journal-title":"Ann Neurol"},{"key":"R6-1-20210203","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S0074-7742(08)60024-0","article-title":"Benzoquinolizine derivatives: a new class of monoamine decreasing drugs with psychotropic action.","volume":"4","author":"Pletscher","year":"1962","journal-title":"Int Rev Neurobiol"},{"key":"R7-1-20210203","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/mds.21222","article-title":"Long-term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders.","volume":"22","author":"Kenney","year":"2007","journal-title":"Mov Disord"},{"key":"R8-1-20210203","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/0169-328X(94)90050-7","article-title":"Synaptic vesicular monoamine transporter expression: distribution and pharmacologic profile.","volume":"22","author":"Gonzalez","year":"1994","journal-title":"Brain Res Mol Brain Res"},{"key":"R9-1-20210203","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/0006-8993(95)00674-F","article-title":"Regional distribution of monoamine vesicular uptake sites in the mesencephalon of control subjects and patients with Parkinson's disease: a postmortem study using tritiated tetrabenazine.","volume":"692","author":"Thibaut","year":"1995","journal-title":"Brain Res"},{"key":"R10-1-20210203","first-page":"450","article-title":"First clinical experiences with tetrabenazine in Italian.","volume":"49","author":"Sacerdoti","year":"1960","journal-title":"Rass Studi Psichiatr"},{"key":"R11-1-20210203","first-page":"277","article-title":"Tetrabenazine in the treatment of hyperkinetic movement disorders.","volume":"37","author":"Jankovic","year":"1983","journal-title":"Adv Neurol"},{"key":"R12-1-20210203","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1136\/bmj.2.5654.422","article-title":"Effect of tetrabenazine on extrapyramidal movement disorders.","volume":"2","author":"Dalby","year":"1969","journal-title":"Br Med J"},{"key":"R13-1-20210203","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1136\/bmj.4.5726.55","article-title":"Tetrabenazine for Huntington's chorea.","volume":"4","author":"Soutar","year":"1970","journal-title":"Br Med J"},{"key":"R14-1-20210203","first-page":"871","article-title":"Drug treatment of diseases characterized by abnormal movements.","volume":"66","author":"Marsden","year":"1973","journal-title":"Proc R Soc Med"},{"key":"R15-1-20210203","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1136\/jnnp.35.2.186","article-title":"Treatment of involuntary movement disorders with tetrabenazine.","volume":"35","author":"Swash","year":"1974","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R16-1-20210203","doi-asserted-by":"crossref","first-page":"583","DOI":"10.5694\/j.1326-5377.1976.tb140870.x","article-title":"Tetrabenazine in the treatment of Huntington's chorea.","volume":"1","author":"Huang","year":"1976","journal-title":"Med J Aust"},{"key":"R17-1-20210203","first-page":"81","article-title":"Tetrabenazine in the treatment of Huntington's chorea and other hyperkinetic movement disorders.","volume":"39","author":"Toglia","year":"1978","journal-title":"J Clin Psychiatry"},{"key":"R18-1-20210203","first-page":"35","article-title":"The treatment of the choreas and athetotic dystonias.","volume":"13","author":"Godwin-Austen","year":"1979","journal-title":"J R Coll Physicians Lond"},{"key":"R19-1-20210203","doi-asserted-by":"crossref","first-page":"628","DOI":"10.5694\/j.1326-5377.1979.tb119426.x","article-title":"Tetrabenazine for involuntary movement disorders.","volume":"1","author":"Kingston","year":"1979","journal-title":"Med J Aust"},{"key":"R20-1-20210203","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1212\/WNL.31.8.1051","article-title":"Tetrabenazine and movement disorders.","volume":"31","author":"Asher","year":"1981","journal-title":"Neurology"},{"key":"R21-1-20210203","first-page":"267","article-title":"Long-term treatment of tardive dyskinesia with presynaptically acting dopamine-depleting agents.","volume":"37","author":"Fahn","year":"1983","journal-title":"Adv Neurol"},{"key":"R22-1-20210203","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1212\/WNL.38.3.391","article-title":"Tetrabenazine therapy of dystonia, chorea, tics, and other dyskinesias.","volume":"38","author":"Jankovic","year":"1988","journal-title":"Neurology"},{"key":"R23-1-20210203","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1212\/WNL.48.2.358","article-title":"Long-term effects of tetrabenazine in hyperkinetic movement disorders.","volume":"48","author":"Jankovic","year":"1997","journal-title":"Neurology"},{"key":"R24-1-20210203","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1097\/00002826-200211000-00003","article-title":"Tetrabenazine treatment for Huntington's disease associated chorea.","volume":"25","author":"Ondo","year":"2002","journal-title":"Clin Neuropharmacol"},{"key":"R25-1-20210203","doi-asserted-by":"crossref","first-page":":230","DOI":"10.1097\/01.wnf.0000136892.24629.96","article-title":"Tetrabenazine treatment in movement disorders.","volume":"27","author":"Paleacu","year":"2004","journal-title":"Clin Neuropharmacol"},{"key":"R26-1-20210203","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/S0140-6736(74)92338-1","article-title":"A double-blind trial of tetrabenazine, thiopropazate, and placebo in patients with chorea.","volume":"1","author":"McLellan","year":"1974","journal-title":"Lancet"},{"key":"R27-1-20210203","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/ana.410110108","article-title":"Treatment of hyperkinetic movement disorders with tetrabenazine: a double-blind crossover study.","volume":"11","author":"Jankovic","year":"1982","journal-title":"Ann Neurol"},{"key":"R28-1-20210203","first-page":"282","article-title":"Huntington disease: tetrabenazine compared to haloperidol in reduction of involuntary movements.","volume":"4","author":"Gimenez-Roldan","year":"1989","journal-title":"Neurologia"},{"key":"R29-1-20210203","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1176\/ajp.156.8.1279","article-title":"Tetrabenazine treatment for tardive dyskinesia: assessment by randomized videotape protocol.","volume":"156","author":"Ondo","year":"1999","journal-title":"Am J Psychiatry"},{"key":"R30-1-20210203","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1212\/01.wnl.0000198586.85250.13","article-title":"Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial.","volume":"66","year":"2006","journal-title":"Neurology"},{"key":"R31-1-20210203","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1002\/mds.870110204","article-title":"Unified Huntington's Disease Rating Scale: reliability and consistency.","volume":"11","year":"1996","journal-title":"Mov Disord"},{"key":"R32-1-20210203","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1212\/01.WNL.0000086373.32347.16","article-title":"Huntington Study Group. Huntington's disease: clinical correlates of disability and progression.","volume":"61","author":"Mahant","year":"2003","journal-title":"Neurology"},{"key":"R33-1-20210203","doi-asserted-by":"crossref","first-page":"3190","DOI":"10.1002\/sim.2245","article-title":"Assessing genetic effects in survival data by correlating martingale residuals with an application to age at onset of Huntington disease.","volume":"25","author":"Wintrebert","year":"2006","journal-title":"Stat Med"},{"key":"R34-1-20210203","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/mds.21222","article-title":"Long-term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders.","volume":"22","author":"Kenney","year":"2007","journal-title":"Mov Disord"},{"key":"R35-1-20210203","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/mds.21161","article-title":"Short-term effects of tetrabenazine on chorea associated with Huntington's disease.","volume":"22","author":"Kenney","year":"2006","journal-title":"Mov Disord"}],"container-title":["Clinical Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00002826-200811000-00001","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,21]],"date-time":"2023-05-21T08:15:14Z","timestamp":1684656914000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00002826-200811000-00001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,11]]},"references-count":35,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2008]]}},"URL":"https:\/\/doi.org\/10.1097\/wnf.0b013e318166da60","relation":{},"ISSN":["0362-5664"],"issn-type":[{"value":"0362-5664","type":"print"}],"subject":[],"published":{"date-parts":[[2008,11]]}}}